drugset / Trial / NCT00381862
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
NaSingle-groupOpen-labelSupportive care
Summary
RATIONALE: Aprepitant, palonosetron, and dexamethasone may help lessen or prevent nausea and vomiting in patients receiving chemotherapy. PURPOSE: This phase II trial is studying how well giving aprepitant together with palonosetron and dexamethasone works in preventing nausea and vomiting caused by chemotherapy in patients receiving chemotherapy for metastatic colorectal cancer.
Timeline
- Start
- 2006-06
- Primary completion
- 2008-03
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aprepitant | Other / unclassified | 80 mg | Oral |
| Subject | Palonosetron | Other / unclassified | 0.25 mg | Intravenous |
| Background | Dexamethasone | Small molecule | 8 mg | Oral |
| Background | Irinotecan | Small molecule | — | — |
| Background | Leucovorin | Small molecule | — | — |
| Background | Oxaliplatin | Small molecule | — | — |
| Background | fluorouracil | Small molecule | — | — |